Aysegul A Sahin, MD

Peer-Reviewed Articles

1. Liang T, Ding QQ, Middleton L, Wu Y, Sahin AA. Characteristics of secretory breast carcinoma with extensive in situ carcinoma components: Clinical and histopathologic analysis. Elsevier 37, 2024. e-Pub 2024.
2. Batra H, Bose PSC, Ding Y, Dai A, Chen H, Albarracin CT, Sun H, Sahin AA, Yang F, Wistuba II, Raso MG. MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers. Histopathology. e-Pub 2024. PMID: 38973399.
3. Salem A, Wu Y, Albarracin CT, Middleton LP, Kalhor N, Peng Y, Huang X, Aung PP, Chen H, Sahin AA, Ding Q. A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland. Hum Pathol 145:42-47, 2024. e-Pub 2024. PMID: 38262580.
4. Huang X, Anderson SA, Siegal GP, Wei S, Liu S, Yang J, Roisin P, Pickens JT, Huo L, Sahin AA, Granada CP, Chen S. Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma. Clin Breast Cancer. e-Pub 2024. PMID: 38492995.
5. Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers (Basel) 16(1), 2023. e-Pub 2023. PMID: 38201434.
6. Batra H, Mouabbi JA, Ding Q, Sahin AA, Raso MG. Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights. Cancers (Basel) 15(22), 2023. e-Pub 2023. PMID: 38001750.
7. Law T, Piotrowski MJ, Ning J, Jiang X, Ding Q, Sahin AA. Trichorhinophalangeal syndrome type 1 (TRPS1) expression in male breast carcinoma. Hum Pathol 138:62-67, 2023. e-Pub 2023. PMID: 37331526.
8. Zhang Y, Zhao Z, Huang LA, Liu Y, Yao J, Sun C, Li Y, Zhang Z, Ye Y, Yuan F, Nguyen TK, Garlapati NR, Wu A, Egranov SD, Caudle AS, Sahin AA, Lim B, Beretta L, Calin GA, Yu D, Hung MC, Curran MA, Rezvani K, Gan B, Tan Z, Han L, Lin C, Yang L. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metab 35(8):1457-1473.e13, 2023. e-Pub 2023. PMID: 37329887.
9. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
10. Zhang X, Yao J, Niu N, Li X, Liu Y, Huo L, Euscher ED, Wang H, Bell D, Sood AK, Wang G, Lawson BC, Ramalingam P, Malpica A, Sahin AA, Ding Q, Liu J. SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. Mod Pathol 36(2):100001, 2023. e-Pub 2023. PMID: 36853778.
11. Batra H, Ding Q, Pandurengan R, Ibarguen H, Rabassedas NB, Sahin A, Wistuba I, Parra ER, Raso MG. Exploration of cancer associated fibroblasts phenotypes in the tumor microenvironment of classical and pleomorphic Invasive Lobular Carcinoma. Front Oncol 13:1281650, 2023. e-Pub 2023. PMID: 38192631.
12. Ordóñez NG, Sahin AA. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study. Hum Pathol 45(7):1529-40, 2014. e-Pub 2014. PMID: 24816068.
13. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer. Clin Cancer Res 20(14):3870-3883, 2014. e-Pub 2014. PMID: 24895461.
14. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional recurrence risk for patients with t1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys 89(2):392-8, 2014. e-Pub 2014.
15. Thompson PA, Ljuslinder I, Tsavachidis S, Brewster A, Sahin A, Hedman H, Henriksson R, Bondy ML, Melin BS. Loss of LRIG1 Locus Increases Risk of Early and Late Relapse of Stage I/II Breast Cancer. Cancer Res 74(11):2928-35, 2014. PMID: 24879564.
16. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM. Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. Mol Cancer Ther 13(5):1382-9, 2014. e-Pub 2014. PMID: 24608573.
17. Hunt KK, Sahin AA. Too much, too little, or just right? Tumor margins in women undergoing breast-conserving surgery. J Clin Oncol 32(14):1401-6, 2014. e-Pub 2014. PMID: 24687821.
18. Caudle AS, Yi M, Hoffman KE, Mittendorf EA, Babiera GV, Hwang RF, Meric-Bernstam F, Sahin AA, Hunt KK. Impact of Identification of Internal Mammary Sentinel Lymph Node Metastasis in Breast Cancer Patients. Ann Surg Oncol 21(1):60-5, 2014. e-Pub 2013. PMID: 24046126.
19. Liu Y, Zhou R, Baumbusch LO, Tsavachidis S, Brewster AM, Do KA, Sahin A, Hortobagyi GN, Taube JH, Mani SA, Aarøe J, Wärnberg F, Børresen-Dale AL, Mills GB, Thompson PA, Bondy ML. Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat 143(1):189-201, 2014. e-Pub 2013.
20. Tannour-Louet M, Lewis SK, Louet JF, Stewart J, Addai JB, Sahin A, Vangapandu HV, Lewis AL, Dittmar K, Pautler RG, Zhang L, Smith RG, Lamb DJ. Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies. FASEB J 28(1):364-72, 2014. e-Pub 2013.
21. Wang J, Mittendorf EA, Sahin AA, Yi M, Caudle A, Hunt KK, Wu Y. Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database. PLoS One 9(2):e89778, 2014. e-Pub 2014. PMID: 24587029.
22. Chen N, Balasenthil S, Reuther J, Frayna A, Wang Y, Chandler DS, Abruzzo LV, Rashid A, Rodriguez J, Lozano G, Cao Y, Lokken E, Chen J, Frazier ML, Sahin AA, Wistuba II, Sen S, Lott ST, Killary AM. DEAR1 is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGFβ-Driven Epithelial-Mesenchymal Transition. Cancer Discov 3(10):1172-89, 2013. e-Pub 2013. PMID: 23838884.
23. Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol 24(10):2534-42, 2013. e-Pub 2013. PMID: 23729783.
24. Zhang S, Huang WC, Zhang L, Zhang C, Lowery FJ, Ding Z, Guo H, Wang H, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res 73(18):5764-74, 2013. e-Pub 2013. PMID: 23913825.
25. Murray JL, Thompson P, Yoo SY, Do KA, Pande M, Zhou R, Liu Y, Sahin AA, Bondy ML, Brewster AM. Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer. Breast Cancer Res Treat 138(3):917-24, 2013. e-Pub 2013. PMID: 23529385.
26. Pande M, Thompson PA, Do KA, Sahin AA, Amos CI, Frazier ML, Bondy ML, Brewster AM. Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis 34(3):587-94, 2013. e-Pub 2012. PMID: 23180655.
27. Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res 15(5):R77, 2013. PMID: 24008095.
28. Kim MM, Dawood S, Allen P, Sahin AA, Woodward WA, Smith BD, Strom EA, Hunt KK, Meric-Bernstam F, Gonzalez-Angulo AM, Buchholz TA. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer 118(20):4936-43, 2012. e-Pub 2012. PMID: 22511276.
29. Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV, Sahin AA, Mittendorf EA. American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Ann Surg Oncol 19(10):3144-51, 2012. e-Pub 2012. PMID: 22847123.
30. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 122(6):2066-78, 2012. e-Pub 2012. PMID: 22585577.
31. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 118(9):2385-93, 2012. e-Pub 2011. PMID: 21953213.
32. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 2012. e-Pub 2011. PMID: 21837669.
33. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, Hortobagyi GN, Gonzalez-Angulo AM, Luo S, Buzdar AU, Crow JR, Kuerer HM, Hunt KK. Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated With Surgery As the First Intervention: Time to Modify the Current American Joint Committee on Cancer Staging System. J Clin Oncol 29(35):4654-61, 2011. e-Pub 2011. PMID: 22084362.
34. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clin Breast Cancer 11(5):325-31, 2011. e-Pub 2011.
35. Brewster AM, Thompson P, Sahin AA, Do K, Edgerton M, Murray JL, Tsavachidis S, Zhou R, Liu Y, Zhang L, Mills G, Bondy M. Copy Number Imbalances Between Screen and Symptom-Detected Breast Cancers and Impact on Disease-free Survival. Cancer Prev Res (Phila) 4(10):1609-16, 2011. e-Pub 2011. PMID: 21795423.
36. Perry KD, Reynolds C, Rosen DG, Edgerton ME, T Albarracin C, Gilcrease MZ, Sahin AA, Abraham SC, Wu Y. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology 59(4):619-30, 2011. PMID: 22014043.
37. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Ann Surg Oncol 18(9):2407-12, 2011. e-Pub 2011. PMID: 21327455.
38. Durak MG, Gonzalez-Angulo AM, Hanrahan EO, Broglio KR, Valero V, Hortobagyi GN, Hunt KK, Sahin AA. Age and Associated Fibrocystic Changes are Prognostically Significant in Patients with Small Node-Negative (T1a,bN0) Invasive Breast Cancer. Breast J 17(5):462-9, 2011. e-Pub 2011. PMID: 21726347.
39. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. J Clin Oncol 29(23):3126-32, 2011. e-Pub 2011. PMID: 21730275.
40. Wagner JL, Warneke CL, Mittendorf EA, Bedrosian I, Babiera GV, Kuerer HM, Hunt KK, Yang W, Sahin AA, Meric-Bernstam F. Delays in Primary Surgical Treatment Are Not Associated with Significant Tumor Size Progression in Breast Cancer Patients. Ann Surg 254(1):119-24, 2011. e-Pub 2011. PMID: 21494124.
41. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. J Clin Oncol 29(19):2628-34, 2011. e-Pub 2011. PMID: 21606433.
42. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Mol Cancer Ther 10(6):1093-101, 2011. e-Pub 2011.
43. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. J Clin Oncol 29(15):1956-62, 2011. e-Pub 2011. PMID: 21482989.
44. Huo L, Bell D, Qiu H,Sahin A, Wu Y, Sneige N. Paneth cell-like eosinophilic cytoplasmic granules in breast carcinoma. Ann Diagn Pathol 15(2):84-92, 2011. e-Pub 2010.
45. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, Sahin AA, Esteva FJ, Hortobagyi GN, Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17(4):461-9, 2011. e-Pub 2011. PMID: 21399647.
46. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Tereffe W, Woodward WA, Strom EA, Hunt KK, Tucker SL, Buchholz TA. Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer 117(8):1595-601, 2011. e-Pub 2010.
47. Agbe AA, Sahin AA, Simmons DL. Bio-repository of breast tissue. Journal of Histotechnology 33(4):169-71, 2010.
48. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177(4):1647-56, 2010. e-Pub 2010. PMID: 20813970.
49. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Strom EA, Tereffe W, Woodward WA, Tucker SL, Hunt KK, Hortobagyi GN, Buchholz TA. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys 77(5):1296-302, 2010. e-Pub 2010.
50. Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, Kamal A, Hsu L, Hortobagyi GN, Sahin AA. Glutathione-S-Transferase-Pi Expression in Early Breast Cancer: Association With Outcome and Response to Chemotherapy. Cancer Invest 28(5):554-9, 2010. e-Pub 2010. PMID: 20210524.
51. Alvarez RH, Booser DJ, Cristofanilli M, Sahin AA, Strom EA, Guerra L, Kau SW, Gonzalez-Angulo AM, Hortobagyi GN, Valero V. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer 116(5):1210-7, 2010. PMID: 20082452.
52. Chen JQ, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Sahin A, Katz R, Bondy M, Hortobagyi G, Berinstein NL, Murray JL, Radvanyi L. Quantitative Immunohistochemical Analysis and Prognostic Significance of TRPS-1, a New GATA Transcription Factor Family Member, in Breast Cancer. Horm Cancer 1(1):21-33, 2010. e-Pub 2010.
53. Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20(6):1013-1019, 2009. e-Pub 2009. PMID: 19237480.
54. Sahin AA, Guray M, Hunt KK. Identification and biologic significance of micrometastases in axillary lymph nodes in patients with invasive breast cancer. Arch Pathol Lab Med 133(6):869-878, 2009. PMID: 19492879.
55. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med 6(5):e1000068, 2009. e-Pub 2009. PMID: 19536326.
56. Loya A, Guray M, Hennessy BT, Middleton LP, Buchholz TA, Valero V, Sahin AA. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer 115(8):1605-1612, 2009. PMID: 19197997.
57. Mittendorf EA, Sahin AA, Tucker SL, Meric-Bernstam F, Yi M, Nayeemuddin KM, Babiera GV, Ross MI, Feig BW, Kuerer HM, Hunt KK. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol 15(12):3369-77, 2008. e-Pub 2008. PMID: 18815841.
58. Gadre SA, Perkins GH, Sahin A, Sneige N, Deavers MT, Middleton LP. Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion. Histopathology 53(5):545-53, 2008. PMID: 18983463.
59. Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA. Locoregional Treatment Outcomes After Multimodality Management Of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys 72(2):474-84, 2008. e-Pub 2008. PMID: 18439768.
60. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084-91, 2008.
61. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Staging of breast cancer in the neoadjuvant setting. Cancer Res 68(16):6477-81, 2008. PMID: 18701468.
62. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 14(3):261-267, 2008. e-Pub 2008. PMID: 18373644.
63. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10(2):138-148, 2008. e-Pub 2008. PMID: 18204439.
64. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 26(2):246-52, 2008. e-Pub 2007. PMID: 18056680.
65. Lee DF, Kuo HP, Chen CT, Hsu JM, Sun HL, Chou CK, Wei Y, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JL, Sahin AA, Hortobagyi GN. Suppression of TSC1 by IKKb confers tumor angiogenesis and diet and obesity-induced insulin resistance. Cell 130(3):440-455, 2007.
66. Brewster AM, Do KA, Thompson PA, Hahn KM, Sahin AA, Cao Y, Stewart MM, Murray JL, Hortobagyi GN, Bondy ML. Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol 25(28):4438-4444, 2007. e-Pub 2007. PMID: 17785707.
67. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, Hung MC. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130(3):440-55, 2007. PMID: 17693255.
68. Dogan BE, Whitman GJ, Singletary ES, Sahin A. Needle localization and excision of lesions poorly visible or invisible on mammography using mammographic landmarks. Breast J 13(4):433-435, 2007.
69. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 68(4):1004-1009, 2007. e-Pub 2007. PMID: 17418973.
70. Middleton LP, Perkins GH, Tucker SL, Sahin AA, Singletary SE. Expression of ERalpha and ERbeta in lobular carcinoma in situ. Histopathology 50(7):875-880, 2007. PMID: 17543077.
71. Abba MC, Fabris VT, Hu Y, Kittrell FS, Cai WW, Donehower LA, Sahin A, Medina D, Aldaz CM. Identification of novel amplification gene targets in mouse and human breast cancer at a syntetic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res 67(8):4101-4012, 2007. e-Pub 2007.
72. Cabioglu N, Hunt KK, Sahin AA, Kuerer HM, Babiera GV, Singletary SE, Whitman GJ, Ross MI, Ames FC, Feig BW, Buchholz TA, Meric-Bernstam F. Role for Intraoperative Margin Assessment in Patients Undergoing Breast-Conserving Surgery. Ann Surg Oncol 14(4):1458-1471, 2007. e-Pub 2007. PMID: 17260108.
73. Huang EH, Strom EA, Valero V, Fornage B, Perkins GH, Oh JL, Yu TK, Tereffe W, Woodward WA, Hunt KK, Meric-Bernstam F, Sahin AA, Bedrosian I, Hortobagyi GN, Buchholz TA. Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. Int J Radiat Oncol Biol Phys 67(2):490-496, 2007. PMID: 17236970.
74. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-233, 2007. PMID: 17200359.
75. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9(4):R57, 2007. PMID: 17764565.
76. Akkiprik M, Nicorici D, Cogdell D, Jia YJ, Hategan A, Tabus I, Yli-Harja O, Y D, Sahin A, Zhang W. Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray. Technol Cancer Res Treat 5(6):543-551, 2006.
77. Yang WT, Lai CJ, Whitman GJ, Murphy WA, Dryden MJ, Kushwaha AC, Sahin AA, Johnston D, Dempsey PJ, Shaw CC. Comparison of full-field digital mammography and screen-film mammography for detection and characterization of simulated small masses. AJR Am J Roentgenol 187(6):W576-81, 2006. PMID: 17114508.
78. Lu J, Wei Q, Bondy ML, Li D, Brewster A, Shete S, Yu TK, Sahin A, Meric-Bernstam F, Hunt KK, Singletary SE, Ross MI, Wang LE. Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women <or=55 years. Carcinogenesis 27(11):2209-2216, 2006. e-Pub 2006.
79. Lu J, Wei Q, Bondy ML, Yu TK, Li D, Brewster A, Shete S, Sahin A, Meric-Bernstam F, Wang LE. Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107(9):2245-2253, 2006.
80. Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys 66(2):352-357, 2006. e-Pub 2006. PMID: 16887286.
81. Xia WY, Lien HC, Wang SC, Pan Y, Sahin A, Kuo YH, Chang KJ, Zhou X, Wang H, Yu Z, Hortobagyi G, Shi DR, Hung MC. Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer. Breast Cancer Res Treat 98(3):295-301, 2006. e-Pub 2006.
82. Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 118(11):2703-2710, 2006. PMID: 16381000.
83. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cristofanilli M. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 17(6):945-951, 2006.
84. Guray M, Sahin AA. Benign breast diseases: classification, diagnosis, and management. Oncologist 11(5):435-449, 2006. PMID: 16720843.
85. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 106(5):1000-1006, 2006.
86. Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243(2):257-264, 2006. PMID: 16432360.
87. Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res 11(23):8398-8402, 2005. PMID: 16322301.
88. Strom EA, Woodward WA, Katz A, Buchholz TA, Perkins GH, Jhingran A, Theriault R, Singletary E, Sahin A, McNeese MD. Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Radiat Oncol Biol Phys 63(5):1508-1513, 2005.
89. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23(36):9304-9311, 2005.
90. Diaz LK, Cristofanilli M, Zhou X, Welch KL, Smith TL, Yang Y, Sneige N, Sahin AA, Gilcrease MZ. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol 18(9):1165-1175, 2005. PMID: 15920552.
91. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin A, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983-5992, 2005. e-Pub 2005. PMID: 16087943.
92. Vadlamudi RK, Manavathi B, Balasenthil S, Nair SS, Yang Z, Sahin AA, Kumar R. Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res 65(17):7724-7732, 2005. PMID: 16140940.
93. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 11(16):5686-5693, 2005.
94. Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 104(4):676-681, 2005. PMID: 15981280.
95. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, Pumiglia K, Gallick GE, Price JE. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 65(15):6493-6497, 2005. PMID: 16061624.
96. Cabioglu N, Hunt KK, Buchholz TA, Mirza N, Singletary SE, Kuerer HM, Babiera GV, Ames FC, Sahin AA, Meric-Bernstam F. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer 104(1):20-29, 2005. PMID: 15912514.
97. Montero AJ, Rouzier R, Lluch A, Theriault RL, Buzdar AU, Delaloge S, Bermejo B, Le M, Kau SW, Dunant A, Arriagada R, Spielmann M, Garcia-Conde J, Sahin AA, Singletary SE, Hortobagyi GN, Valero V. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer 104(2):229-235, 2005. PMID: 15937910.
98. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-3685, 2005. e-Pub 2005. PMID: 15738535.
99. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 62(2):351-357, 2005. PMID: 15890574.
100. Vadlamudi RK, Balasenthil S, Sahin AA, Kies M, Weber RS, Kumar R, El-Naggar AK. Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets. Hum Pathol 36(6):670-675, 2005. PMID: 16021574.
101. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11(9):3315-3319, 2005. PMID: 15867229.
102. Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11(9):3309-3314, 2005.
103. Vadlamudi RK, Barnes CJ, Rayala S, Li F, Balasenthil S, Marcus S, Goodson HV, Sahin AA, Kumar R. p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B. Mol Cell Biol 25(9):3726-3736, 2005. PMID: 15831477.
104. Shahar KH, Buchholz TA, Delpassand E, Sahin AA, Ross MI, Ames FC, Kuerer HM, Feig BW, Meric-Bernstam F, Babiera GV, Singletary SE, Akins JS, Mirza NQ, Hunt KK. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer 103(7):1323-1329, 2005. PMID: 15726547.
105. Chagpar A, Middleton LP, Sahin AA, Meric-Bernstam F, Kuerer HM, Feig BW, Ross MI, Ames FC, Singletary SE, Buchholz TA, Valero V, Hunt KK. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 103(8):1581-1586, 2005. PMID: 15747375.
106. Maru D, Middleton LP, Wang S, Valero V, Sahin A. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger. Cancer 103(5):1581-1586, 2005.
107. Abba MC, Hu Y, Sun H, Drake JA, Gaddis S, Baggerly K, Sahin A, Aldaz CM. Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics 6(1):37, 2005.
108. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Babiera G, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy. Cancer 103(4):689-95, 2005. PMID: 15641036.
109. Cabioglu N, Sahin AA, Doucet M, Yavuz E, Igci A, O Yildirim E, Aktas E, Bilgic S, Kiran B, Deniz G, Price JE. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis 22(1):39-46, 2005.
110. Yuan Y, Liu H, Sahin A, Dai JL. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer 113(4):654-659, 2005.
111. Nunez MI, Ludes-Meyers J, Abba MC, Kil H, Abbey NW, Page RE, Sahin A Klein-Szanto AJ, Aldaz CM. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 89(2):99-105, 2005.
112. Mangala LS, Arun B, Sahin AA, Mehta K. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer 4:33-41, 2005. e-Pub 2005. PMID: 16153302.
113. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 22(23):4691-9, 2004. PMID: 15570071.
114. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10(23):8068-76, 2004. PMID: 15585642.
115. Dai JL, Wang L, Sahin AA, Broemeling LD, Schutte M, Pan Y. NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer. Oncogene 23(53):8681-7, 2004. PMID: 15467753.
116. Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 101(9):1977-86, 2004. PMID: 15389473.
117. Hu Y, Sun H, Drake J, Kittrell F, Abba MC, Deng L, Gaddis S, Sahin A, Baggerly K, Medina D, Aldaz CM. From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res 64(21):7748-55, 2004.
118. Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, Meric-Bernstam F, Aldaz MC, Hortobagyi GN, Pusztai L. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat 87(3):205-214, 2004.
119. Baykal A, Rosen D, Zhou C, Liu J, Sahin AA. Telomerase in breast cancer: a critical evaluation. Adv Anat Pathol 11(5):5686-5693, 2004. PMID: 15322492.
120. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 59(5):1337-42, 2004. PMID: 15275718.
121. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117-127, 2004. PMID: 15324695.
122. Yared MA, Middleton LP, Meric F, Cristofanilli M, Sahin AA. Expression of c-kit proto-oncogene product in breast tissue. Breast J 10(4):323-7, 2004. PMID: 15239791.
123. Shahar KH, Hunt KK, Thames HD, Ross MI, Perkins GH, Kuerer HM, Strom EA, McNeese MD, Meric F, Schechter NR, Sahin AA, Middleton LP, Buchholz TA. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys 59(4):1074-9, 2004. PMID: 15234041.
124. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW,Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22(12):2303-2312, 2004. PMID: 15197191.
125. Vadlamudi RK, Bagheri-Yarmand R, Yang Z, Balasenthil S, Nguyen D, Sahin AA, den Hollander P, Kumar R. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 5(6):575-85, 2004. PMID: 15193260.
126. Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, Poìndexter N, Roth JA, Ramesh R, Grimm EA, Mhashilkar AM. MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. Int Immunopharmacol 4(5):649-67, 2004. PMID: 15120650.
127. Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz TA. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 59(1):138-45, 2004.
128. Liu J, Baykal A, Fung KM, Thompson-Lanza JA, Hoque A, Lippman SM, Sahin A. Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. Int J Oncol 24(4):879-84, 2004.
129. Resetkova E, Sahin A, Ayala AG, Sneige N. Breast carcinoma with choriocarcinomatous features. Ann Diagn Pathol 8(2):74-9, 2004.
130. Diaz LK, Sahin A, Sneige N. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. Ann Diagn Pathol 8(1):23-7, 2004.
131. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100(3):499-506, 2004. PMID: 14745865.
132. Ivan D, Selinko V, Sahin AA, Sneige N, Middleton LP. Accuracy of core needle biopsy diagnosis in assessing papillary breast lesions: histologic predictors of malignancy. Mod Pathol 17(2):165-71, 2004. PMID: 14631369.
133. Shen SS, Sahin AA. Invasive ductal carcinoma of the breast with a microglandular adenosis pattern. Ann Diagn Pathol 8(1):39-42, 2004. PMID: 15129910.
134. Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, Gaddis S, Sahin A, Baggerly K, Aldaz CM. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res 6(5):R499-513, 2004.
135. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK, Kumar R. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 279(2):1422-8, 2004. e-Pub 2003. PMID: 14530270.
136. Buchholz, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Multidisciplinary considerations involved in using neoadjuvant chemotherapy for breast cancer. Am J of Oncol Rev 3(3):156-164, 2004.
137. Poindexter NJ, Sahin A, Hunt KK, Grimm EA. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res 6(4):R408-15, 2004.
138. Royce ME, Xia W, Sahin AA, Katayama H, Johnston DA, Hortobagyi G, Sen S, Hung MC. STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 100(1):12-9, 2004. PMID: 14692019.
139. Ko BK, Efferson CL, Kawano K, Kuerer HM, Sahin A, Murray JL, Ioannides CG. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2 (+) tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes. Int J Oncol 24(6):1413-1418, 2004.
140. Diaz LK, Zhou X, Welch K, Sahin A, Gilcrease MZ. Chromogenic in situ hybridization for alpha 6 beta 4 integrin in breast cancer correlation with protein expression. J Mol Diagn 6(1):10-15, 2004.
141. Hoque A, Carter J, Xia W, Hung MC, Sahin AA, Sen S, Lippman SM. Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev 12(12):1518-22, 2003. PMID: 14693746.
142. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res 9(15):5652-9, 2003. PMID: 14654548.
143. Garg AK, Hortobagyi GN, Aggarwal BB, Sahin AA, Buchholz TA. Nuclear factor-kappa B as a predictor of treatment response in breast cancer. Curr Opin Oncol 15(6):405-11, 2003. PMID: 14624221.
144. Chagpar A, Yen T, Sahin A, Hunt KK, Whitman GJ, Ames FC, Ross MI, Meric-Bernstam F, Babiera GV, Singletary SE, Kuerer HM. Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg 186(4):371-7, 2003.
145. Woodward WA, Strom EA, Tucker SL, Katz A, McNeese MD, Perkins GH, Buzdar AU, Hortobagyi GN, Hunt KK, Sahin A, Meric F, Sneige N, Buchholz TA. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 57(2):336-44, 2003.
146. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 98(6):1150-60, 2003. PMID: 12973838.
147. Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer 98(5):1055-60, 2003.
148. Zhu J, Chang P, Bondy ML, Sahin AA, Singletary SE, Takahashi S, Shirai T, Li D. Detection of 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine-DNA adducts in normal breast tissues and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 12(9):830-7, 2003. PMID: 14504191.
149. Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res 9(10 pt 1):3660-3666, 2003. PMID: 14506155.
150. Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, Mendez R, Dai JL. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 63(15):4724-30, 2003.
151. Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes CJ, Kumar R. HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res 9(8):3198-203, 2003. PMID: 12912973.
152. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 63(14):4174-80, 2003. PMID: 12874023.
153. Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R. Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett 543(1-3):76-80, 2003. PMID: 12753909.
154. Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res 9(3):955-60, 2003. PMID: 12631592.
155. Diaz LK, Hunt K, Ames F, Meric F, Kuerer H, Babiera G, Ross M, Singletary E, Middleton LP, Symmans WF, Krishnamurthy S, Sahin A, Sneige N, Gilcrease MZ. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol 27(3):385-9, 2003.
156. Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu ET, Hortobagi GN. Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study. Cancer Genet Cytogenet 141(2):148-53, 2003.
157. Talukder AH, Mishra SK, Mandal M, Balasenthil S, Mehta S, Sahin AA, Barnes CJ, Kumar R. MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions. J Biol Chem 278(13):11676-85, 2003. e-Pub 2003. PMID: 12527756.
158. Middleton LP, Grant S, Stephens T, Stelling CB, Sneige N, Sahin AA. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised?. Mod Pathol 16(2):120-9, 2003. PMID: 12591964.
159. Sneige N, Lim SC, Whitman GJ, Krishnamurthy S, Sahin AA, Smith TL, Stelling CB. Atypical ductal hyperplasia diagnosis by directional vacuum-assisted stereotactic biopsy of breast microcalcifications. Considerations for surgical excision. Am J Clin Pathol 119(2):248-53, 2003. PMID: 12579995.
160. Lifshitz OH, Whitman GJ,Sahin AA, Yang WT. Radiologic-pathologic conferences of the University of Texas M. D. Anderson Cancer Center. Phyllodes Tumor of the Breast. AJR Am J Roentgenol 180(2):332, 2003. PMID: 12540427.
161. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 9(1):33-41, 2003. PMID: 12602766.
162. Gilcrease MZ, Sahin AA. Detection of Ductal Carcinoma in Situ by Screening Mammography: Pathologic Features Important for Clinical Management. Breast Dis 13(4):316-322, 2003.

Invited Articles

1. Kwon Y, Sahin AA. Commentary on: Intraoperative imprint cytology examination of sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients. Breast Diseases: A Year Book Quarterly 22(1):72-73, 2011.
2. Guray M, Sahin AA. Commentary on: Metaplastic Breast Carcinomas: Are They of Myoepithelial Differentiation? Immunohistochemical Profile of the Sarcomatoid Subtype Using Novel Myoepithelial Markers. Breast Diseases: A Year Book Quarterly 16(4):359, 2006.
3. Sahin AA. Commentary on: Pathologic Features of Breast Cancer Associated With Complete Response to Neoadjuvant Chemotherapy: Importance of Tumor Necrosis. Breast Diseases: A Year Book Quarterly 17(1):56-57, 2006.
4. Sahin AA. Commentary on: The Optimal Number of Sentinel Lymph Nodes for Focused Pathologic Examination. Breast Diseases: A Year Book Quarterly 16(1):64, 2005.
5. Sahin AA. Commentary on: Intraoperative Evaluation of Sentinel Lymph Nodes for Breast Cancer. Breast Diseases: A Year Book Quarterly 16(2):120-125, 2005.
6. Sahin AA. Commentary on: 1–17 Patterns of Chromosomal Alterations in Breast Ductal Carcinoma In Situ. Breast Diseases: A Year Book Quarterly 16(1):46-47, 2005.
7. Sahin AA. Commentary on: A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena. Breast Diseases: A Year Book Quarterly 15(3):247-248, 2004.
8. Sahin AA. Commentary on: The hepatocyte growth factor regulatory factors in human breast cancer. Breast Diseases: A Year Book Quarterly 15(3):278, 2004.
9. Gilcrease MZ, Sahin AA. Commentary on: Detection of ductal carcinoma in situ by screening mammography: pathologic features important for clinical management. Breast Diseases: A Year Book Quarterly 13(4):316-323, 2003.
10. Sahin AA. Commentary on: How significant is detection of ductal carcinoma in situ in a breast screening programme. Breast Diseases: A Year Book Quarterly 14(2):143-144, 2003.
11. Sahin AA. Commentary on: Computer-generated nuclear features compared with axillary lymph node status and tumor size as indicators of breast cancer survival. Breast Diseases: A Year Book Quarterly 14(3):292, 2003.

Abstracts

1. Anderson S, Bartow B, Siegal G, Harada S, Khoury K, Yalniz C, Huo L, Ding QQ, Sahin A, Huang X. Predictive Biomarkers for Immune Checkpoint Inhibitor (ICI) and Poly (ADP-Ribose) Polymerase (PARP) Inhibitor (PARPi) in Advanced Stage Breast Carcinoma. Mod Pathol 104(3):S108-09, 2024.
2. Ye Q, Klippel D, Albarracin C, Chen H, Contreras A, Ding QQ, Huo L, Khazai L, Middelton L, Resetkova E, Sahin A, Sun H, Sweeney K, Symmans W, Wu Y, Krishnamurthy. A Prospective Study of Real Time Whole Slide Imaging of Frozen Sections for Intraoperative Evaluation of Axillary Sentinel Lymph Nodes in Breast Cancer. Mod Pathol 104(3):S321-22, 2024.
3. Karakas C, Meier L, Sahin AA, Yi M, Trivedi S, Hunt K, Khandan K. Assessment of Discordances of HER2 Expression and Gene Amplification 10% Versus 30% Cutoff?. USCAP 103rd Annual Meeting, 2014.
4. Walls AL, Sahin AA, El-Naggar AK, Middleton, LP. Basaloid Salivary-Analogue Tumors of the Mammary Gland: Histopathologic Spectrum and Differential Diagnosis. USCAP 103rd Annual Meeting, 2014.
5. Bousamra A, Luthra R, Lu X, Aldape KD, Sahin AA, Singh RR, Lu G, Abraham R. Quantitative Assessment of Her2 Using Molecular Inversion Probe Arrays in Patients with High Grade Tumors Expressing Her2 Amplification by FISH. USCAP 103rd Annual Meeting, 2014.
6. Chowdhuri SR, Routbort M, Patel, KP, Singh R, Broaddus R, Lazar A, Sahin A, Mills G, Mendelsohn J, Meric-Bernstam F, Aldape K, Luthra R. Multi-Gene Mutational Profiling of Breast Carcinoma Using Next Generation Sequencing (NGS). USCAP 103rd Annual Meeting, 2014.
7. Drinka E, McBride A, Allen P, Buchholz T, Sahin A. Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients with Stage II Breast Cancer. USCAP 102nd Annual Meeting, 2013.
8. Karak S, Middleton LP, Yi M, Hunt KK, Sahin AA. Intraoperative Margin Assessment Significantly Improves Quality of Care in Patients Undergoing Breast Conserving Surgery. USCAP 102nd Annual Meeting, 2013.
9. Shen Q, Ibrahim NK, Aldape KD, Sahin AA. Breast Cancer with Brain Metastases: Risk Factors and Survival. USCAP 102nd Annual Meeting, 2013.
10. Khazai L, Middleton LP, Goktepe N, Liu BT, Sahin AA. Breast Pathology Second Review Identifies Clinically Significant Discrepancies in 10% of Cases. USCAP 101th Annual Meeting, 2012.
11. Karakas C, Biernacka A, Sahin A, Hunt K, Keyomarsi K. Cytoplasmic Staining Pattern of Cyclin E andpCDK2 Expression Correlates with Poor Outcome in Breast Cancer (BC) Patients (pts). USCAP 101th Annual Meeting, 2012.
12. Chen JQ, Xiao L, Wu Y, Litton J, Zhou R, Shen X, Sahin AA, Katz RL, Bondy M, Murray JL, Radvanyi LG. Higher TRPS-1 Expression Independently Predicts Better Clinical Outcome in ER+ Breast Cancer. USCAP 101th Annual Meeting, 2012.
13. Rosen DG, Middleton LP, Yang WT, Sahin AA. Selection of Breast Core Biopsy Specimens for Tissue Bio-Repository. USCAP 101th Annual Meeting, 2012.
14. Dallas NK, Yi M, Hunt K, Shah RR, Kuerer HM, Litton JK, Wu Y, Caudle AS, Meric-Bernstam F, Sahin AA, Mittendorf EA. Evaluation of the stage IB designation of the 7th edition of the AJCC Staging System. ASCO 2012 Annual Meeting, 2012.
15. Zhou J, Rosen D, Brouquet A, Abbott D, Loyer EM, Meric-Bernstam F, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey JN, Sahin A, Maru D. Pathologic Response and Tumor Thickness at Tumor-Normal Interface (TNI): Potential Prognostic Factors of Disease-Free Survival (DFS) in Liver Metastases of Breast Cancer (LMBC). USCAP 100th Annual Meeting, 2011.
16. Rosen GD, Sahin AA. Relationship between implementation of the American Society of Clinical Oncology/College of American Pathologists guideline recommendations for breast core-needle biopsies and delay in therapy for patients with breast cancer. ASCO 2011 Breast Cancer Symposium, 2011.
17. Biernacka A, Karakas C, Wingate H, Bondy M, Sahin A, Hunt K, Khandan K. Cytoplasmic Cyclin E and P-CDK2 Expression in Triple Negative Breast Carcinomas Measured by Immunohistochemistry Correlates with Poor Outcome. San Antonio Breast Cancer Symposium, 2011.
18. Raghav KPS, Hernandez-Aya LF, Lei X, Chavez-Mac Gregor M, Meric-Bernstam F, Buchholz TA, Sahin AA, Do K, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen-and progesteron-receptor expression on survival outcomes in breast cancers previously classified as triple-negative breast cancers. ASCO 2011 Annual Meeting, 2011.
19. Chavez-MacGregor M, Lei X, Litton JK, Melham A, Mittendorf EA, Meric-Bernstam F, Sahin AA, Valero V, Hortobagy GN, Gonzalez-Angulo AM. Predictors of recurrence among patients with breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant systemic chemotherapy. ASCO 2011 Annual Meeting. Chicago, IL, 2011.
20. Bayraktar S, Gonzalez-Angulo AM, Buzdar LA, Valero V, Melhem A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracyclin-based regimens for HER2-positive breast cancer. ASCO 2011 Annual Meeting, 2011.
21. Murray JL, Thompson P, Zhou R, Yoo SY, Do LK, Sahin AA, Bondy M, Brewster AM. Prognostic value of single nucleotide polymorphisms (SNPs) of candidate genes associated with inflammation in early-stage breast cancer. ASCO 2011 Annual Meeting. Chicago, IL, 2011.
22. Yi M, Mittendorf EA, Buchholz TA, Sahin AA, Kuerer HM, Luo S, Bilimoria KY, Crow J, Cormier JN Gonzalea-Angulo AM, Buzdar A, Hortobagyi GN, Junt K. A novel staging system for disease-specific survival in patients with breast cancer treated with surgery as the first intervention. ASCO 2011 Breast Cancer Symposium, 2011.
23. Chen S, Albarracin CT, Wang H, Klein K, Sahin A, Wang HM. Downregulation of hematopoietic progenitor kinase 1 protein level in ductal carcinoma in situ and invasive ductal carcinoma of the breast. USCAP 99th Annual Meeting, 2010.
24. Leng X, Shui R, Shen L, Baggerly KA, Liu X, Sahin A, Abraham SC, Wu Y. High resolution analysis of genome-wide copy number change in neuroendocrine carcinoma of the breast. USCAP 99th Annual Meeting, 2010.
25. Shim JY, Zhou R, Thompson PA, Brewster AM, Murray JL, Edgerton ME, Karadag N, Bondy ML, Sahin A. Biomarker expression can identify biologically distinct categories of invasive breast cancer. USCAP 99th Annual Meeting, 2010.
26. Wei B, Tian Z, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova ER, Middleton LP, Sahin A, Chen J, Abraham SC, Wu Y. Prognostic factors of primary invasive mammary neuroendocrine carcinoma: clinicopathologic analysis of 4 cases. USCAP 99th Annual Meeting, 2010.
27. Bambury RM, Gonzalez-Angulo A-M, Carey MS, Sahin A, Brown P, Speers C, Lluch A, Mills GB, Hennessy BT. Caveolin 1 and patient outcomes in breast cancer. San Antonio Breast Cancer Symposium, 2010.
28. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar A, Hortobagyi GN, Hunt KK. Validation of a novel staging system for disease-specific survival in breast cancer patients treated with neoadjuvant chemotherapy. San Antonio Breast Cancer Symposium, 2010.
29. Chen JQ, Litton J, Xiao L, Zhang H-Z, Warneke CL, Wu Y, Shen X, Sahin A, Katz R, Murray JL, Radvanyi. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. San Antonio Breast Cancer Symposium, 2010.
30. Gadre SA, Perkins GH, Sahin AA, Sneige N,Deavers MT, Middleton LP. Neovascularization in Mucinous Ductal Carcinoma In Situ Suggests an Alternative Pathway for Invasion. USCAP 98th Annual Meeting, 2009.
31. Krishnamurthy S, Tang S, Wang X, Sahin AA, Pantoja LM, Lucci A, Kuerer HM, Babiera G, Bedrosian I, Hunt KK, Meric-Bernstam F. Utility of a one-step nucleic acid amplification (OSNA) assay for comprehensive examination of axillry lymph nodes in breast cancer. San Antonio Breast Cancer Symposium, 2009.
32. Yang W, Sahin A, Wong H, Tsimelzon A, Hess K, Karadag N, Cairo M, Meric F, Arun B, Chang JC. Molecular portraits of mammographic breast density in normal breast tissue. ASCO 2008 Annual Meeting, 2008.
33. Alvarez RH, Kau S, Strom EA, Sahin AA, Singletary SE, Booser DJ, Cristofanilli M, Esteva FJ, Hortobagyi GN, Valero V. Phase II study of primary systemic therapy (PST) with doxorubicin (D) and docetaxel (T), then surgery (S), and radiation (RT), followed by use of non-cross-resistant adjuvant chemotherapy (Adj CT) with CMF based on pathologic response, in patients (pts) with locally advanced breast cancer (LABC): Long-term results from study ID97-099, MD Anderson Cancer Center. ASCO 2008 Annual Meeting, 2008.
34. Yang WT, Lewis MT, Wong H, Hess K, Tsimelzon A, Karadag N, Cairo M, Meric-Bernstam F, Sahin A, Chang JC. Decreased TGFβ signaling and increased COX2 expression in high risk women with increased mammographic breast density. San Antonio Breast Cancer Symposium, 2008.
35. Rakkhit R, Broglio K, Peintinger F, Cardoso F, Hanrahan EO, Litton JK, Sahin A, Larsimont D, Meric-Bernstam F, Buchholz TA, Valero V, Theriault RL, Piccart M, Ravdin P, Hortobagyi GN, Gonzalez-Angulo AM. Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. San Antonio Breast Cancer Symposium, 2008.
36. Shaye AN, Sahin AA, Huo L, Woodward WA. Labeling pattern of breast cancer stem phenotype in invasive breast carcinomas: an immunohistochemical analysis. San Antonio Breast Cancer Symposium, 2007.
37. Kelten C, Mittendorf EA, Broglio K, Vo T, Middleton LP, Ueno N, Hunt KK, Sahin AA. Clinical significance of occult axillary lymph node metastses in breast cancer patients without adjuvant systemic therapy: a long term retrospective study. San Antonio Breast Cancer Symposium, 2007.
38. Uzquiano MC, Resetkova E, Arribas E, Sahin A. Mitotic index evaluated with Phosphohistone H3 as only predictor of outcome on surgical excision in challenging fibroepithelial lesions. USCAP 96th Annual Meeting, 2007.
39. Middleton LP, Perkins GH, Tucker SL, Sahin AA, Singletary SE. Expression of ERa and ERb in lobular carcinoma in situ. USCAP 96th Annual Meeting, 2007.
40. Guray M, Gonzalez-Angulo AM, Hanrahan EO, Broglio K, Valero V, Hortobagyi G, Sahin AA. Histopathologic evaluation of small node-negative (T1a,bN0) invasive breast cancer (IBC). Prognostic significance of associated ductal carcinoma in situ (DCIS) and fibrocystic changes (FCC). USCAP 96th Annual Meeting, 2007.
41. Loya A, Guray M, Hennessy B, Middleton LP, Buchholz T, Valero V, Sahin AA. Detection of Occult Metastatic Carcinoma in Patients Who Had Initial Cytologically Proven Positive Axillary Lymph Nodes with Subsequent Complete Pathologic Response Following Pre-Operative Chemotherapy for Locally Advanced Breast Cancer. An Immunohistochemical Study. USCAP 95th Annual Meeting, 2006.
42. Huo L, Sahin AA. Morphologic features of ipsilateral recurrent breast cancers in patients treated with breast conserving therapy (BCT). Mod Pathol 18(1):36A, 2005.
43. Williams MD,Sahin AA. Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expressed in salivary duct adenocarcinoma: Potential therapeutic targets. Mod Pathol 18(1):218A, 2005.
44. McGuire SE, Sahin AA. Radiation is an important component of therapy for patients with stage III breast cancer who achieve a pathological complete response after neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 63(2):S52, 2005.
45. Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA, Hortobagyi GN, Buchholz TA.. Comparison of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys 63(2):S250, 2005.
46. Meric-Bernstam F, Zhang H, Lotan R, Lotan D, Sahin A, Babiera GV, Kopelovich L, Corwell JA, Strong LC. Feasibility of the use of primary breast epithelial cell cultures to identify genotype-specific preventive agents. J Clin Oncol 23(16):226S, 2005.
47. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Soria JC, Cristofanilli M. The pattern of chemokin receptors expressed by tumor cells predicts the site of metastatic relapse in patients with axillary node positive breast cancer. J Clin Oncol 23(16):837S, 2005.
48. Cabioglu N, Gong Y, Sneige N, Sahin A, Gonzalez-Angulo AM, Bucana C, Morandi P, Hortobagyi G, Cristofanilli M. Increased expression of chemokin receptors in inflammatory breast cancer. Implications for novel targeted therapies. J Clin Oncol 23(16):874S, 2005.
49. Rouzier R. Pathological nodal status after anthracycline-based primary systemic therapy (PST) predicts 10-year prognosis of patients with large operable locally advanced breast cancer. Breast Cancer Res Treat 88:S49-50, 2004.
50. Cabioglu N, Sahin AA. Novel biomarkers predicting axillary lymph node metastasis in small size breast cancer. Breast Cancer Res Treat 88:S113-S114, 2004.
51. Cabioglu N, Sahin AA. Improving local control with breast-conserving therapy: A 27-year single institution experience. Breast Cancer Res Treat 88(S165-S166), 2004.
52. Cabioglu N. Intraoperative margin assessment in breast-conserving surgery. Breast Cancer Res Treat 88:S16, 2004.
53. Arun B, Sahin AA. The combination of letrozole and imatinib mesylate for metastatic breast cancer. Breast Cancer Res Treat 88(S235-S236), 2004.
54. Korapati AL. JAB1-mediated p27Kip1 degradation as a prognostic factor and a novel therapeutic target for breast cancer. Cancer Epidemiol Biomarkers Prev 13(11):1913S-1914S, 2004.
55. Gupta D, Sahin AA. . Male breast cancer: Clinico-pathological study with evaluation of biologic markers. J Clin Oncol 22(14):71S, 2004.
56. Davis WG, Sahin AA. Paxillin overexpression: A reporter of Her-2/neu activity that predicts response to docetaxel/herceptin™chemotherapy. Mod Pathol 17(1):28A, 2004.
57. Gokhale S,Sahin AA. Assessment of two automated systems of imaging technology in evaluation of estrogen receptor status in invasive carcinoma of breast. Mod Pathol 17(1):32A, 2004.
58. Kim E, Sahin AA. Absence of E-cadherin expression in invasive ductal carcinoma of breast: A significant predictor of lymph node metastasis. Mod Pathol 17(1):36A, 2004.
59. Wang H, Sahin AA. The role of IGFBP2 and IGFBP5 overexpression in metastasis of T1 breast carcinomas. Mod Pathol 17(1):53A, 2004.
60. Zhang H. Amount of tumor present in core needle biopsy (CNB) samples: A significant predictor of margin status in subsequent breast-conserving surgery (BCS) specimens in patients with ductal carcinoma in situ (DCIS). Mod Pathol 17(1):55A, 2004.
61. Sun W. Clinicopathologic and immunohistochemical (IHC) features of lung cancer in women with a history of primary breast cancer (PBC). Mod Pathol 17(1):344A, 2004.
62. Albarracin CT, Sahin AA. Cell-specific dysregulation of annexin I expression in breast cancer. Mod Pathol 16(1):21A, 2003.
63. Cohn M, Sahin AA. Gastrointestinal metastases of carcinoma of the breast. Mod Pathol 16(1):26A, 2003.
64. Diaz L, Sahin AA. Immunohistochemical detection of estrogen receptor in breast cancer: A laboratory quality improvement study. Mod Pathol 16(1):27A, 2003.
65. Gokhale S, Sahin AA. Immunohistochemical expression of prostate specific antigen in normal breast tissue and breast neoplasms. Mod Pathol 16(1):29A, 2003.
66. Goncharuk V, Sahin AA. Assessment of actin-binding protein fascin expression in stage I and II invasive breast cancer. A significant correlation with aggressive clinical behavior. Mod Pathol 16(1):30A, 2003.
67. Ivan D, Sahin AA. Accuracy of core needle biopsy diagnosis in assessing papillary breast lesions: Histologic predictors of malignancy. Mod Pathol 16(1):34A, 2003.
68. Krishnamurthy S, Sahin AA. Intraoperative imprint cytology for evaluation of axillary sentinel lymph nodes in breast cancer. Mod Pathol 16(1):37A, 2003.
69. Lee P, Sahin AA. Expression of androgen receptor coactivator 70 in stage I and II invasive breast cancer. Mod Pathol 16(1):38A, 2003.
70. Maru D, Sahin AA. p53 and HER2 neu expression in breast carcinoma occurring in young women. Mod Pathol 16(1):40A, 2003.
71. Zhai Q, Sahin AA. Cyclin D1 and p27 expression correlates with response to trastuzumab therapy in patients with HER-2-overexpressing metastatic breast cancer. Mod Pathol 16(1):51A, 2003.
72. Buchholz TA, Sahin AA. Lack of bcl-2 and bax expression correlates with pathological complete response to doxorubicin-based neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 82:S71, 2003.
73. Cabioglu N, Sahin AA. CXCR4 as a potential predictive marker for detection of tumor cells in bone marrow of patients with breast cancer. Breast Cancer Res Treat 82:S73, 2003.
74. Cabioglu N, Sahin AA. CXCR4 as a potential predictive marker for detection of tumor cells in bone marrow of patients with breast cancer. Breast Cancer Res Treat 82:S73, 2003.
75. Buchholz TA, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in breast cancer patients treated with doxorubicin-based neoadjuvant chemotherapy. Breast Cancer Res Treat 82:S112, 2003.
76. Huang EH, Sahin AA. Predictors of local-regional recurrences in patients with locally-advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy and radiation. Breast Cancer Res Treat 82:S182, 2003.
77. Garg A, Sahin AA. Clinical stage T3 disease or pathologic involvement of four or more lymph nodes predict for local-regional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiation. Breast Cancer Res Treat 82:S182-183, 2003.
78. Forehand F, Sahin AA. The relationship between Sialyl-Tn(STn) and c-erb-B-2 expression in invasive breast cancer. USCAP Annual Meeting 1998, 1998.
79. Sahin AA. Clinicopathologic features of bilateral breast cancer. USCAP 87th Annual Meeting, 1998.
80. Sneige N, Sahin AA. Interobserver reproducibility (IR) of the Lagios nuclear grading system for ductal carcinoma in situ (DCIS). USCAP 87th Annual Meeting, 1998.

Book Chapters

1. Wu Y, Sahin AA. Molecular Classification and Testing of Breast Carcinoma. In: Rosen's Breast Pathology. Fourth. Wolters Kluwer: Philadelphia, PA, 1337 - 1349, 2014.
2. Sahin A, Brown AS. Diagnosis and biomarkers. In: Personalized Management of Breast Cancer. Future Medicine Ltd: London, 6-19, 2014.
3. Karakas C, Resetkova E, Sahin AA. Papillary Lesions of the Breast. In: Difficult Diagnoses in Breast Pathology. Demos Medical: New York, 56-87, 2011.
4. Shim JY, Sahin AA. Mucinous Lesions of the Breast. In: Surgical Pathology Clinics - Current Concepts in Breast Pathology. Second. W.B. Saunders: Philadelphia, 413-440, 2009.
5. McKenzie-Johnson T, Sahin A, Hunt KK. Sentinel lymph node dissection: Indications, technique and results. In: Advanced Therapy in Surgical Oncology. BC Decker Inc: Hamilton, Ontario, 511-522, 2008.
6. Guray M, Sahin AA. Pathology of Invasive Breast Carcinoma. In: Atlas of Cancer. second. Springer Science: New York, NY, 422-425, 2008.
7. Gilcrease MZ, Sahin AA. Pathological Evaluation of Axillary Sentinel Lymph Nodes in Breast Cancer. In: Methods Mol Med. Humana Press: Totowa, NJ, 113-127, 2006.
8. Sahin AA. Pathology of Invasive Breast Cancer. In: Breast Cancer. Second. BC Decker Inc: Hamilton, Ontario, 198-216, 2006.
9. Sahin AA. Surgical Margin Evaluation in Patients Treated with Breast-Conserving. In: Advanced Therapy of Breast Disease. Second, 341-348, 2004.

Letters to the Editor

1. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity?. Arch Pathol Lab Med 134: 162-3; author reply 163, 2010.